Two ACR Convergence 2026 studies tie GLP-1 receptor agonists to lower cardiovascular and mortality risk.
|Articles|February 26, 2010
Haiti: We Care Solar Suitcase Demonstration
View a demo of a We Care Solar Suitcase here. This tool was used by many healthcare professionals who spent time in Haiti
Advertisement
View a demo of a We Care Solar Suitcase here. This tool was used by many healthcare professionals who spent time in Haiti.
Advertisement
Related to this article
Two ACR 2026 abstracts report rising cardiovascular deaths in Sjögren syndrome and superior ESSDAI response with baricitinib vs hydroxychloroquine.
Kate Harnden, MBChB, PhD, discusses models predicting persistent arthritis after checkpoint inhibitor therapy, presented at EULAR 2026 and as an ACR plenary.
Jack Arnold and Rihards Buss preview 6 ACR 2026 abstracts spanning ICI arthritis, PsA proteomics, JAK inhibitor prescribing, and B-cell depletion.
The FDA approved tildrakizumab for adults with active psoriatic arthritis based on two phase 3 trials showing improved ACR20 response at week 24 vs placebo.
Buss and Arnolds discuss underscore persistent gaps between gout guideline recommendations and real-world practice.
Jessica Gordon, MD, MS, and New York rheumatologists discuss who to screen for ILD, how to monitor without overimaging, and when to add antifibrotics.
Koji Ishikawa, MD, PhD, emphasized that 12 months of romosozumab showed benefits for osteoporosis.
Advertisement
Advertisement
Trending on Rheumatology Live
1
INSPIRE: Joint, Skin Gains Support Tildrakizumab PsA Approval: Philip Mease, MD
2
Joint Ventures ACR 2026 Preview: 6 Abstracts Rheumatologists Should Watch
3
Monitoring and Caring for Adult Patients with Progressive Pulmonary Fibrosis
4
Predicting Persistent Arthritis After ICI Therapy: Kate Harnden, MBChB, PhD
5